Morgan Stanley analyst Terence Flynn raised the firm’s target price in Bristol Myers (BMY) to $40 from $37 and maintains an underweight rating on the stock. 2026 revenue and EPS guidance came in above consensus, but was driven by higher-than-expected Eliquis guidance, the analyst tells investors in a research note.
Claim 50% off TipRanks Premium
-
unlock data at the hedge fund level i powerful investment tools to make more intelligent and correct decisions
-
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
Posted first The Fly – The ultimate source of real-time, breaking financial news that moves the market. Try now >>
Check out today’s top performing stocks on TipRanks >>
Read more about BMY:
Disclaimer and DisclosureReport a problem
-
trump Trade: Argentina says US will cut hundreds of tariffs
-
Bristol Myers’ price target rose to $72 from $62 at Guggenheim
-
Bristol Myers’ price target rose to $60 from $55 at Wells Fargo





